{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:37Z","timestamp":1787019577017,"version":"build-2736575974"},"reference-count":16,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R\/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R\/R MCL therapy across 15 international centers, and studied those experiencing POD post\u2013CAR T-cell therapy in detail. We extracted clinical\/treatment\/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response to CAR T-cell therapy. Tumor features at POD included blastoid\/pleomorphic morphology in 29 of 78 (37%) patients, and TP53 mutation in 21 of 41 (51%) patients. Following POD, 17 patients received no further therapy, 13 underwent local therapy, and 105 received systemic therapy. The most common first-line systemic therapies were chemo(immuno)therapy (22 patients; overall response rate [ORR], 40%), pirtobrutinib (17 patients; ORR, 36%), and bispecific antibodies (13 patients; ORR, 67%). Among patients experiencing POD, the median progression-free survival and overall survival (OS) were 2.5 months and 5.4 months, respectively, from POD. Lack of response to CAR T-cell therapy and short time from CAR T-cell therapy infusion to POD (&amp;lt;3 vs 3-6 vs &amp;gt;6 months), among other factors, were associated with inferior OS after POD. In conclusion, we confirm the challenging prognosis for patients experiencing POD following CD19 CAR T-cell therapy for R\/R MCL, and establish a benchmark for future investigations in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016315","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T19:08:43Z","timestamp":1754420923000},"page":"5654-5662","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Treatment and outcomes of progression of disease post\u2013CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5942-2502","authenticated-orcid":false,"given":"Zachary D.","family":"Epstein-Peterson","sequence":"first","affiliation":[{"name":"1Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7174-7070","authenticated-orcid":false,"given":"Anath C.","family":"Lionel","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-5666","authenticated-orcid":false,"given":"Ashlee","family":"Joseph","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3315-4538","authenticated-orcid":false,"given":"Esther","family":"Drill","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3380-5326","authenticated-orcid":false,"given":"Suheil Albert","family":"Atallah-Yunes","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4352-9296","authenticated-orcid":false,"given":"Taylor R.","family":"Brooks","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8895-1625","authenticated-orcid":false,"given":"Elise A.","family":"Chong","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA"},{"name":"8Department of Medicine, Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline R.","family":"Chong","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA"},{"name":"8Department of Medicine, Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Dela Cruz","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"10Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ip","sequence":"additional","affiliation":[{"name":"11Lymphoma Division, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[{"name":"12Department of Hematology\/Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-152X","authenticated-orcid":false,"given":"Manali K.","family":"Kamdar","sequence":"additional","affiliation":[{"name":"13Department of Medicine, University of Colorado, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"14Division of Hematology and Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofrat","family":"Beyar-Katz","sequence":"additional","affiliation":[{"name":"15Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel"},{"name":"16The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[{"name":"17Division of Hematology, The James Cancer Center, The Ohio State University Hospital, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew J.","family":"Matasar","sequence":"additional","affiliation":[{"name":"18Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3697-9623","authenticated-orcid":false,"given":"Daniel","family":"McLoughlin","sequence":"additional","affiliation":[{"name":"14Division of Hematology and Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid W.","family":"Merryman","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier L.","family":"Munoz","sequence":"additional","affiliation":[{"name":"19Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Navalekar","sequence":"additional","affiliation":[{"name":"18Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5068-9040","authenticated-orcid":false,"given":"Joanna","family":"Rhodes","sequence":"additional","affiliation":[{"name":"18Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0580","authenticated-orcid":false,"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[{"name":"20David and Etta Jonas Center for Cellular Therapy, Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-1943","authenticated-orcid":false,"given":"Christine E.","family":"Ryan","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medicine, New York, NY"},{"name":"21Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-3671","authenticated-orcid":false,"given":"Yazeed","family":"Sawalha","sequence":"additional","affiliation":[{"name":"17Division of Hematology, The James Cancer Center, The Ohio State University Hospital, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8892-3456","authenticated-orcid":false,"given":"Samanvaya","family":"Sharma","sequence":"additional","affiliation":[{"name":"18Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8032","authenticated-orcid":false,"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Weill Cornell Medicine, New York, NY"},{"name":"21Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navika","family":"Shukla","sequence":"additional","affiliation":[{"name":"18Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9423-1941","authenticated-orcid":false,"given":"Dylan","family":"Therwhanger","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA"},{"name":"8Department of Medicine, Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5456-6408","authenticated-orcid":false,"given":"Herman","family":"van Besien","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-7303","authenticated-orcid":false,"given":"Ben","family":"Varon","sequence":"additional","affiliation":[{"name":"15Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel"},{"name":"16The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4616-8568","authenticated-orcid":false,"given":"Samuel","family":"Yamshon","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-6883","authenticated-orcid":false,"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medicine, New York, NY"},{"name":"21Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-5810","authenticated-orcid":false,"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"6","key":"2025111111210938800_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"10","key":"2025111111210938800_bib2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025111111210938800_bib3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"2025111111210938800_bib4","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025111111210938800_bib5","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1111\/bjh.17197","article-title":"Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy","volume":"192","author":"Jain","year":"2021","journal-title":"Br J Haematol"},{"key":"2025111111210938800_bib6","first-page":"02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"23","author":"Phillips","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111111210938800_bib7","author":"R Core Team","year":"2020"},{"issue":"8","key":"2025111111210938800_bib8","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"issue":"24","key":"2025111111210938800_bib9","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025111111210938800_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"10","key":"2025111111210938800_bib11","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3390\/cancers14102516","article-title":"Glofitamab treatment in relapsed or refractory DLBCL after CAR T-cell therapy","volume":"14","author":"Rentsch","year":"2022","journal-title":"Cancers"},{"issue":"suppl 1","key":"2025111111210938800_bib12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: initial results from a phase Ib\/II study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2025111111210938800_bib13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2025111111210938800_bib14","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"2025111111210938800_bib15","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1080\/10428194.2023.2241095","article-title":"Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease","volume":"64","author":"Lew","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025111111210938800_bib16","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP 53 alterations","volume":"184","author":"Lin","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5654\/2419638\/blooda_adv-2025-016315-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5654\/2419638\/blooda_adv-2025-016315-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:21:16Z","timestamp":1762878076000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/21\/5654\/546492\/Treatment-and-outcomes-of-progression-of-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":16,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016315","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,11]]},"published":{"date-parts":[[2025,11,11]]}}}